Anónimo. Sofosuvir: hypertensions artérielles pulmonaires?. Prescrire 2016;36:746. [Ref.ID 100893]

Anónimo. Elbasvir/grazoprevir (Zepatier) for hepatitis C. The Medical Letter on Drug and Therapeutics Bulletin 2016;58:25-7. [Ref.ID 100126]

Anónimo. Hepatitis C combination drug may shorten duration of treatment to four weeks, mid-stage trial shows. DIA Daily 2016:3. [Ref.ID 100004]

Anónimo. Daclatasvir. Prescrire 2015;35:738-9. [Ref.ID 99846]

Anónimo. Lédipasvir + sofosbuvir. Prescrire 2015;35:732-8. [Ref.ID 99845]

Anónimo. Riesgo de bradicardia grave con el uso concomitante de amiodarona y los nuevos antivíricos para la hepatitis C. Butlletí de Farmacovigilància de Catalunya 2015;13:5-7. [Ref.ID 99830]

Anónimo. Abordaje de la hepatitis C. ¿Tiempos para la esperanza?. Boletín de Información Farmacoterapéutica de Navarra 2015;23:1-10. [Ref.ID 99823]

Anónimo. Daclatasvir (Daklinza) for HCV genotype 3 infection. The Medical Letter on Drug and Therapeutics Bulletin 2015;57:142-3. [Ref.ID 99813]

Gray AL, Wirtz VJ, 't Hoen EFM, Reich MR, Hogerzeil HV. Essential medicines are still essential. Lancet 2015;386:1601-3. [Ref.ID 99632]

Collins JM, Raphael KL, Terry C, Cartwright EJ, Pillai A, Anania FA, Farley MM. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir. Clin Infect Dis 2015;61:1304-6. [Ref.ID 99556]

Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, Sherman KE, Dretler R, Fishbein D, Gathe JC, Henn S, Hinestrosa F, Huynh C, McDonald C, Mills A, Overton ET, Ramgopal M, Rashbaum B, Ray G, Scarsella A, Yozviak J, McPhee F, Liu Z, Hughes E, Yin PD, Noviello S, Ackerman P, for the ALLY-2 Investigators. Daclastavir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015;373:714-25. [Ref.ID 99507]

Muir AJ, Poordad F, Lalezari J, Everson G, Dore GJ, Herring R, Sheikh A, Hézode C, Pockros PJ, Tran A, Yozviak J, Neau N, Ramji A, Stuart K, Thompson AJ, Vierling J, Freilich B, Cooper J, Ghesquiere W, Yang R, McPhee F, Hughes EA, Swenson ES, Yin PD. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA 2015;313:1736-44. [Ref.ID 99085]

Poordad F, Sievert W, Mollison L, Bennett M, Tse E, Bräu N, Levin J, Sepe T, Lee SS, Angus P, Conway B, Pol S, Boyer N, Bronowicki J-P, Jacobson I, Muir AJ, Reddy KR, Tam E, Ortiz-Lasanta G, de Lédinghen V, Sulkowski M, Boparai N, McPhee F, Hughes E, Swenson S, Yin PD, for the UNITY-1 Study Group. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. JAMA 2015;313:1728-35. [Ref.ID 99084]

Najafzadeh M, Andersson K, Shrank WH, Krumme AA, Matlin OS, Brennan T, Avorn J, Choudhry NK. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med 2015;162:407-19. [Ref.ID 98960]

Anónimo. Relatos salvajes del primer mundo. Farmacología virtual 2015;9:1. [Ref.ID 98859]

Gane E. Hepatitis C beware—the end is nigh. Lancet 2014;384:1557-60. [Ref.ID 98307]

Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng C-Y, Chang T-T, Everson GT, Heo J, Gerken G, Yoffe B, Towner WJ, Bourliere M, Metivier S, Chu C-J, Sievert W, Bronowicki J-P, Thabut D, Lee Y-J, Kao J-H, McPhee F, Kopit J, Mendez P, Linaberry M, Hughes E, Noviello S, on behalf of the HALLMARK-DUAL Study Team. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 2014;384:1597-605. [Ref.ID 98304]

Liang TJ, Ghany MG. Therapy of hepatitis C. Back to the future. N Engl J Med 2014;370:2043-7. [Ref.ID 97487]

Editorial. Only just the begining of the end hof hepatiis C. Lancet 2014;383:281. [Ref.ID 97073]

Sulkowski MS, Gardiner DF, Rodríguez-Torres M, Rajender Reddy K, Hassanein T, Jacobson I, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR, Everson GT, Eley T, Wind-Rotolo M, Huang SP, Gao M, Hernandez D, McPhee F, Sherman D, Hindes R, Symonds W, Pasquinelli C, Grasela DM, for the AI444040 Study Group. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370:211-21. [Ref.ID 97027]